129 related articles for article (PubMed ID: 19249557)
1. Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines.
Heuer M; Benkö T; Cicinnati VR; Kaiser GM; Sotiropoulos GC; Baba HA; Treckmann JW; Broelsch CE; Paul A
Transplant Proc; 2009; 41(1):359-65. PubMed ID: 19249557
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.
Shirouzu Y; Ryschich E; Salnikova O; Kerkadze V; Schmidt J; Engelmann G
J Surg Res; 2010 Apr; 159(2):705-13. PubMed ID: 19482307
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.
Zhang JF; Liu JJ; Lu MQ; Cai CJ; Yang Y; Li H; Xu C; Chen GH
Transpl Immunol; 2007 Apr; 17(3):162-8. PubMed ID: 17331842
[TBL] [Abstract][Full Text] [Related]
4. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
7. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
8. Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta.
Martin PM; Aeder SE; Chrestensen CA; Sturgill TW; Hussaini IM
Oncogene; 2007 Jan; 26(3):407-14. PubMed ID: 16832347
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.
Lock HR; Sacks SH; Robson MG
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F76-81. PubMed ID: 16896187
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs.
Gordon IK; Ye F; Kent MS
Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.
Shen Y; Wang X; Xia W; Wang C; Cai M; Xie H; Zhou L; Zheng S
Transplant Proc; 2008 Jun; 40(5):1727-33. PubMed ID: 18589181
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro.
Salas-Prato M; Assalian A; Mehdi AZ; Duperré J; Thompson P; Brazeau P
J Glaucoma; 1996 Feb; 5(1):54-9. PubMed ID: 8795734
[TBL] [Abstract][Full Text] [Related]
15. [The role of caspase-3 in rapamycin-induced apoptosis of hepatocellular carcinoma BEL-7402 cells].
Zhang JF; Lu MQ; Cai CJ; Yang Y; Li H; Yi HM; Chen GH
Ai Zheng; 2006 Dec; 25(12):1508-11. PubMed ID: 17166376
[TBL] [Abstract][Full Text] [Related]
16. Toward the definition of immunosuppressive regimens with antitumor activity.
Casadio F; Croci S; D'Errico Grigioni A; Corti B; Grigioni WF; Landuzzi L; Lollini PL
Transplant Proc; 2005 Jun; 37(5):2144-7. PubMed ID: 15964362
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition.
Zhao YM; Zhou Q; Xu Y; Lai XY; Huang H
Acta Pharmacol Sin; 2008 Apr; 29(4):481-8. PubMed ID: 18358095
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
Hoogduijn MJ; Crop MJ; Korevaar SS; Peeters AM; Eijken M; Maat LP; Balk AH; Weimar W; Baan CC
Transplantation; 2008 Nov; 86(9):1283-91. PubMed ID: 19005411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
